|
|
|
|
| LEADER |
01790nam a2200217 u 4500 |
| 001 |
EB002000564 |
| 003 |
EBX01000000000000001163465 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Sevelamer for the treatment of patients with chronic kidney disease
|h Elektronische Ressource
|b a review of clinical and cost-effectiveness
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, 21 September 2016
|
| 300 |
|
|
|a 1 PDF file (33 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summery with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK395761
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a A 2009 CADTH rapid review of the clinical effectiveness of sevelamer hydrochloride (HCL) for the treatment of chronic kidney disease (CKD) found that sevelamer HCL appeared to be as effective as calcium-based phosphate binders in the management of hyperphosphatemia in CKD patients on dialysis without inducing hypercalcemia. While there was evidence to suggest that sevelamer HCL may slow down the progression of vascular calcification, there was no evidence on its impact on mortality outcomes, and the evidence on its effectiveness on aortic calcification was inconsistent. The report concluded that the published literature at the time did not appear to support the routine use of sevelamer HCL in patients on dialysis. This report reviews the clinical and cost-effectiveness of sevelamer (i.e., HCL or carbonate) for use in patients with CKD.
|